Revvity (NYSE:RVTY – Get Rating) is one of 44 public companies in the “Analytical instruments” industry, but how does it contrast to its rivals? We will compare Revvity to similar companies based on the strength of its institutional ownership, dividends, analyst recommendations, earnings, valuation, profitability and risk.
Risk & Volatility
Revvity has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Comparatively, Revvity’s rivals have a beta of 1.03, suggesting that their average stock price is 3% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and target prices for Revvity and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Revvity | 0 | 0 | 1 | 0 | 3.00 |
| Revvity Competitors | 196 | 1130 | 1732 | 62 | 2.53 |
Dividends
Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.3%. Revvity pays out 3.6% of its earnings in the form of a dividend. As a group, “Analytical instruments” companies pay a dividend yield of 0.4% and pay out 7.5% of their earnings in the form of a dividend.
Profitability
This table compares Revvity and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Revvity | 28.94% | 11.17% | 5.83% |
| Revvity Competitors | -298.81% | -224.28% | -17.23% |
Insider and Institutional Ownership
85.2% of Revvity shares are held by institutional investors. Comparatively, 55.8% of shares of all “Analytical instruments” companies are held by institutional investors. 0.5% of Revvity shares are held by insiders. Comparatively, 15.6% of shares of all “Analytical instruments” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Revvity and its rivals top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Revvity | $3.02 billion | $569.18 million | 14.46 |
| Revvity Competitors | $1.12 billion | -$234.91 million | -32.68 |
Revvity has higher revenue and earnings than its rivals. Revvity is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Summary
Revvity beats its rivals on 11 of the 15 factors compared.
Revvity Company Profile
Revvity, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment consists of technologies that help life sciences researchers better understand diseases and develop treatments. The Diagnostics segment offers instruments, reagents, assay platforms, and software to hospitals, medical labs, clinicians, and medical research professionals to help improve the health of families. The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.
